Plasminogen activator inhibitor-1 (PAI-1) is a specific and rapid inhibitor of tissue plasminogen activator (tPA) and urokinase. Clinical studies suggest that PAI-1 may play a crucial role in the regulation of fibrinolysis. A number of factors modulate PAI-1 activity in endothelial cell culture, and the isolation of PAI-1 cDNA now allows study of PAI-1 regulation at the mRNA level. We examined the effect of endothelial cell growth factor (ECGF) and heparin on PAI-1 expression in human umbilical vein endothelial cell (HUVEC) culture. The addition of ECGF and heparin to HUVEC cultures results in a 3-10-fold decrease in the PAI-1 activity secreted into the conditioned media. This effect is mediated at the mRNA level. A decrease in PAI-1 is also seen with higher concentrations of ECGF alone, but is greatly enhanced by the addition of heparin. No significant change in tPA antigen or mRNA levels was observed.
Introduction
The plasminogen activators, tissue plasminogen activator (tPA)1 and urokinase (uPA), both convert plasminogen into its active form, plasmin, with subsequent degradation of polymerized fibrin. Plasminogen activators may be involved in a number of other biologic processes including ovulation, embryo implantation, neovascularization, and tissue repair (1) . Additionally, tPA appears to be the primary physiologic plasminogen activator in plasma (2) . Two major classes of rapidly acting specific inhibitors oftPA and uPA have been described. These are now designated plasminogen activator inhibitor-l (PAl-1) and plasminogen activator inhibitor-2 (PAI-2) (3). PAI-l is the major form of plasminogen activator inhibitor 1 . Abbreviations used in this paper: ECGF, endothelial cell growth factor; ECGS, ECGF supplement; HUVEC, human umbilical vein endothelial cell; PAI-1, plasminogen activator inhibitor-1; PGK, phosphoglycerate kinase; RFA, reverse fibrin autography; tPA, tissue plasminogen activator; uPa, urokinase.
found in the plasma of males and nonpregnant females (4) . It is a 50-54-kD, acid-stable glycoprotein. An immunologically identical protein has been identified in platelets, endothelial cells, hepatoma cells, and fibrosarcoma cells (5) (6) (7) . The vascular endothelial cell is thought to be the major site of syntheses for tPA, and may be a major synthetic source ofplasma PAI-l as well. PAI-1 constitutes up to 12% of released protein in bovine endothelial cell culture (1) . It rapidly inhibits both tPA and uPA via the formation of a covalent enzyme-inhibitor complex which is stable to low pH and denaturants. PAI-l appears to be present in both a latent and active form (8) .
Clinical studies suggest that PAI-I may play a crucial role in the regulation of fibrinolysis. Elevated PAI-l levels have been observed in a variety of pathologic conditions associated with thrombosis (4, 9, 10) . The accelerated fibrinolysis found in patients with cirrhosis has been correlated with decreased tPA inhibition (1 1).
Human umbilical vein endothelial cell (HUVEC) culture has been used to study the regulation of PAI-1 synthesis in vitro. Propagation of HUVECs in culture requires an artificial support for cell matrix deposition and attachment and the addition of the bovine neuropeptide endothelial cell growth factor (ECGF) to the culture media (12, 13). Further supplementation of the media with heparin markedly enhances cell growth (14) . Heparin has been shown to increase the affinity of ECGF for its receptor, probably through a conformational change in the ECGF peptide (15) .
Several factors are known to affect PAI-I activity and tPA antigen levels in HUVEC-conditioned media. Interleukin-1 increases PAl-1 activity (16) (17) (18) , and this increase requires protein synthesis (17). tPA antigen levels are unchanged (17) or slightly decreased (18) after interleukin-1 stimulation. Thrombin increases both PAI-I activity (19, 20) and tPA antigen levels (19) . Endotoxin markedly increases PAI-M activity (16, 20, 21) , but does not affect tPA levels (20) . Histamine increases tPA antigen levels but does not affect PAI-1 activity (20) . Protein C decreases PAI-1 activity in such culture systems, but this effect appears to be due to the direct action of protein C on the PAI-I protein (22) .
With the recent isolation of PAI-1 cDNA (23) (24) (25) (26) , the regulation of PAM-i synthesis can now be readily studied at the mRNA level. By nucleotide sequence analysis, PAl-1 cDNA encodes a protein containing 402 amino acids with a predicted, nonglycosylated molecular mass of 45 kD. There is extensive homology between PAI-I and other members of the serine protease inhibitor supergene family. Cultured HUVECs contain two PAI-1 mRNA species both encoded by a single gene and differing only in the presence of an additional 1 kb in the 3'-untranslated region of the larger message (23) .
We have examined the effect of ECGF and heparin on PAI-1 expression in HUVEC. The addition of ECGF and hep-arn to HUVEC cultures results in a 3-10-fold decrease in the PAI-1 activity secreted into the conditioned media. This effect is mediated at the mRNA level. A decrease in PAI-l is also seen with high concentrations of ECGF alone but is greatly enhanced by the addition of heparin to the culture media. Methods HUVEC culture. HUVECs were propagated from pooled primary cultures of human umbilical veins (gift of S. Weiss, University of Michigan) as previously described (12, 13). Cells were grown on gelatin ( (27) . Briefly, cells were gently scraped into guanidine HC1 using a rubber policeman. This solution was then sonicated and centrifuged to remove cellular debris, and the RNA was serially ethanol-precipitated from guanidine HCl followed by phenol extraction and further bthanol precipitation. The RNA was quantified by optical density at 260 nm and by visual estimation of ribosomal RNA content by ethidium bromide staining after electrophoresis in a denaturing formaldehyde gel (28 Corp., Arlington Heights, IL) through a vacuum manifold slot blot apparatus (Hybrislot, Bethesda Research Laboratories, Gaithersburg, MD). In both methods, the RNA was fixed to the nylon membrane with ultraviolet irradiation, prehybridized in I M NaCl, 0.1% SDS, and 10% dextran for 3 h at 680C, and hybridized at 680C for 12-24 h in the prehybridization solution with the addition of 3 mg/ml sonicated salmon sperm DNA and the appropriate radiolabeled probe. Probes used included (a) PAI-I cDNA, the 2-kb Ec6RI insert of PAIB6 (23) ; (b) tPA cDNA (kindly provided by S. Degan, University of Cincinnati), the 2-kb BglII fragment (middle probe) of full-length tPA cDNA (29) ; (c) thrombosporqdin cDNA (kindly provided by V. Dixit, University of Michigan), the 1.9-kb Sacd fiagment from the 5' end of the cDNA (30); (d) 8.2-kb full-length von Willebrand factor (vWF) cDNA constructed from clones pvWH33, pvWH7, atnd pvWE6 (27) ; and (e) cDNA for the "housekeeping gene" jphosphoglycerate kihase (PGK), the 1.8-kb PstI insert of pHPGK-7e (31). cDNA inserts were radiolabeled directly in low melting agarose by"random hexamer priming (32).
The blots were washed to high stringency (0.1 X SSC, 0.1% SDS, 1 mM EDTA [pH 8], 10 mM sodium phosphate [pH 6.8], at 680C) and analyzed by autoradiography with 1 Cronex intensifying screen (Dupont Co., Hoffman Estates, IL) at -700C over a wide range ofexposure times (2 h to 7 d). Individual blots were rehybridized with a second radiolabeled probe after incubation in 5 mM Tris HCI (pH 7.5), 2 mM EDTA (pH 8), 0.1 X Denhardt's at 680C for 3-4 h to remove the original probe, with successful "stripping" confirmed by autoradiography.
Densitometric analysis. Densitometric analysis was performed using the GS300 scanning densitometer and the GS 350 data system (Hoefer Scientific Instruments, San Francisco, CA). Serial twofold dilutions of total cellular RNA from cells grown under designated conditions were analyzed by slot blotting using radiolabeled PAl-i ycDNA as probe (see above). Autoradiography was performed for multiple time periods in order to obtain exposures in the linear range ofthe film; the latter was determined by scanning slot blots oftwofold dilutions of cold PAI-I cDNA plasmid probed with radiolabeled PAI-l cDNA. Slot blots exposed within the linear range were selecftd by visual comparison to the standard film. Densitometry results were normalized to scans of the same blot reprobed with PGK. the data were analyzed statistically using the paired Student t test (33) .
PAI-I functional activity. PAI-I functional activity was measured both by re~erse fibrin autography (RFA) (34) and by use ofa commercial amidolytic assay kit (Spectrozyme, American Diagnostica, Greenwich, CT). RFAs were performed after sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SOS-PAGE) through a 3% stacking, 8% running gel. The gel was soaked in 2.5% Triton for 90 min and then applied to a fibrin agar film (1% low-melting agarose, 2.4 mg/ml fibrinogen, 0.4 U/ml thrombin, 0.2 U/ml plasminogen) to which either 3 IU oflow molecular Weight urokinase or 1 IUJ oftPA had been added.
Lysis-free zones were analyzed by photographing the plate after h of incubation. The areas oflysis inhibition' were traced on paper, cut out, and weighed on aft anialytical balance for quantification (34) . The Spectrozyme assay weasure's PAI-I functional activity by the inactivation of a known amount of exogenously added tPA. PAI-I activity is expressed as units of tPA inhibited per milliliter of the assay sathple.
tPA antigen levels. tPA antigen levbls were determined using the Imubind-5 tPA Elisa kit (Alnerican Diagnostica). Levels were determined in conditidned media alone, in conditioned media with JL-ysine (Sigma Chemical Co.) added after harvesting (0.5 M final concentration), and in conditioned media to which heparin (100 ug/ml final concentration) had been added after harvesting.
Results
Decrease in HUVEC-secreted PAI-I activity with the addition of heparin. Varying concentrations of heparin were added to HUVEC cultures in the presence of 100 ,ug/ml ECGS. PAI-1 functional activity in the conditioned media was measured using both the Spectrozyme assay and RFA. Using the Spectrozyme assay, a progressive decrease in PAI-l functional activity in the conditioned media was observed with increasing heparin concentration as shown in Fig. 1 . Assays were performed on media from cells grown in the presence of the test concentration of heparin for two passages and harvested at confluency at the fifth passage. The, results §hown are the mean values ±2 SD from three independent experiments. The difference between the PAI-l functigdal activity in conditioned media from cells grown in the absence,of heparin for two passages (6.27±0.11 IU/ml) vs. PAI-i functional activity in media from cells grown in the presence of 100 ,ug/ml heparin (i .23±0.6) was significatt with a P value < 0.01 (paired t test). Unconditioned media contained no significant PAI-I activity by this assay. Samples were also studied by RFA as shown in Fig. 2 A. With incubation spontaneous lysis and clearing ofthe fibrin film occurred, except in areas of PAI-l activity which appear as opaque, lysis-resistant zones. There is a progressive decrease in the size ofthe protected zone with increasing heparin concentrations. Minimal inhibition is seen from 100% FBS and no PAI-I activity is detected by this assay in control unconditioned media with or without added heparin to 100
,gg/ml.
Secreted PAI-I activity in primary HUVEC cultures. To determine whether this observed decrease in PAI-1 activity in the presence of heparin and its dependence on ECGF (see below) are dependent on HUVEC passage in culture, conditioned media from primary HUVEC cultures were studied. A similar effect on PAI-1 was observed in conditioned media from primary HUVEC cultures. Cells were maintained for 3 d in media containing both heparin and ECGS, heparin without ECGS, ECGS without heparin, or neither heparin nor ECGS. The media were evaluated by RFA as shown in Fig. 2 B. Media from cells grown in both heparin and ECGS produce the smallest lysis-resistant zone and media from cells grown in neither ECGS nor heparin produce the largest lysis-resistant zone, similar to the results seen with fifth passage HUVEC (Fig. 2 A) . Intermediate values were seen with heparin alone or ECGF alone. These results were confirmed in four independent experiments from two separate pooled primaries. In one experiment the results were also confirmed using the Spectrozyme assay. Because of limitations of cell number, additional studies at the mRNA level were performed on passaged HUVEC.
Studies of HUVEC PAI-1 mRNA. Northern blot analysis of total cellular RNA prepared from cells maintained in media containing ECGS (100 gg/ml) either with or without supplemental heparin (100 Atg/ml) is shown in Fig. 3 ,ug/ml ECGS and varying concentrations of heparin from 0 to 100 ,g/ml. 10-,ul aliquots of these conditioned media, "unconditioned" media, or FBS were subjected to SDS-PAGE. (Fig. 3 B) . Similar results were obtained in six independent experiments. In order to more precisely quantify this decrease in PAI-l mRNA, serial twofold dilutions of 4 ,g of total cellular RNA from HUVEC cultures grown either with or without supplemental heparin were applied to nylon filters in a slot blot apparatus. Slot blot filters were probed with PAI-M cDNA, then "stripped," and rehybridized with PGK cDNA, as control. Analysis of pooled densitometric data from three independent experiments reveals a 4.4±1.4-fold decrease in PAI-l mRNA in the presence of heparin (mean±2 SD). Fig. 4 A shows Northern blot analysis of total RNA prepared from HUVEC grown in media supplemented with heparin over a range ofconcentrations for two passages. A maximal decrease in PAI-I mRNA is already evident at 10 Mg/ml of heparin. The same blot reprobed with PGK as control (Fig. 4  B) reflects minor variation in the quantity of mRNA loaded in each lane which may account for some of the differences in PAI-1 mRNA signal intensities. A maximal effect on PAI-1 mRNA observed at heparin concentrations of 10, 50, and 100 ,ug/ml was confirmed by quantitative slot blot analysis. 24 h after a change to fresh media without heparin, PAI-I mRNA had returned to levels similar to those observed in cells grown without supplemental heparin for two passages. A simi- lar decrease in HUVEC PAI-1 mRNA with the addition of heparin was also seen in RNA from cells harvested during log-phase growth, although the difference was less marked than that observed in confluent cells. Northern blot and slot blot analyses of RNA from cells grown with or without supplemental heparin in the culture media were also probed with cDNAs for the endothelial specific protein, von Willebrand factor, and the matrix protein, thrombospondin. No significant changes in the levels of mRNA for these proteins were observed (data not shown).
ECGF requirementfor the decrease in PAI-I mRNA. Fig. 5 shows analysis of cells maintained in media containing varying concentrations of heparin and ECGS. In the absence of supplemental ECGS, the addition of heparin (100 ,g/ml) to the culture media produced no decrease in PAI-1 mRNA (lanes 1 and 2), and at these concentrations, both agents were required for the effect (lane 3). In a separate experiment (lanes 4-6), supplementation of HUVEC culture media with high concentrations of ECGS (500 ,g/ml) (lane 5) in the absence of heparin did show an effect on PAI-1 mRNA, intermediate between the level seen with both heparin (100 Mg/ml) and ECGS (100 ,ug/ml) (lane 6) or ECGS (100 ,g/ml) alone (lane 4). A heparin concentration of 200 ,ug/ml in the absence of ECGS produced no decrease in PAI-1 mRNA (data not shown). In a separate experiment, HUVECs were maintained in media with 4 ng/ml of purified ECGF with or without supplemental heparin. As shown in Fig. 6 , the same results are seen with purified ECGF with or without heparin (lanes 3 and 4) with the more crude ECGS preparation with or without heparin (lanes I and 2) . Thus the observed changes in PAI-1 mRNA with the addition of heparin appear to be due to an interaction with ECGF and not a contaminant in the ECGS preparation.
Effect ofECGF/heparin on tPA expression in HUVEC. tPA antigen levels were measured in conditioned media from HUVEC grown with or without supplemental heparin for two passages. tPA antigen levels were reproducibly higher in conditioned media from cells grown with supplemental heparin (+ media) than in media from cells without heparin supplementation (-media). However, these differences are probably due to increased tPA detection in the presence of heparin. Wun and Capuano (35) have shown that a number of compounds, including heparin, increase tPA antigen detection in normal pooled plasma, with the greatest effect seen with L-lysine and heparin. Addition of heparin (100 ,gg/ml final concentration) to "-media" abolished the difference in tPA antigen levels between the latter and "+ media." A similar effect was seen with the addition of L-lysine (0.5 M final concentration) to both samples. 
100
For each experiment blots were probed with PAI-I cDNA and then reprobed with PGK to document equivalent amount of mRNA in all 00 three lanes.
The effect of heparin/ECGS on HUVEC tPA mRNA was also evaluated. Northern blot analysis of 5 gg total cellular RNA from cells cultured in media containing ECGS with or without supplemental heparin and probed with radioactive cDNA for tPA is shown in Fig. 6 (lanes 5 and 6). No significant difference in the tPA mRNA level was seen.
Discussion PAI-1 may serve as a major control point in the regulation of fibrinolysis via its rapid interaction with tPA. Both thrombotic and hemorrhagic disorders in humans have been associated with alterations in PAI-1 and/or tPA activity (4, 9-1 1). The vascular endothelium may represent the major site of synthesis for plasma PAI-1 (1). A number of factors have been reported to affect PAI-1 activity in endothelial cell culture, although these have not generally been studied at the mRNA level. We have shown that ECGF/heparin decreases HUVEC PAI-I activity in both passaged and primary HUVEC cell culture and that this effect is mediated at the mRNA level. Net fibrinolytic activity reflects a balance between tPA and PAI-1. Changes in one level could be offset or accentuated by changes in the other. ECGF/heparin supplementation of HUVEC culture media does not significantly affect tPA antigen or mRNA levels and thus the observed decrease in PAI-l should produce a net increase in fibrinolytic activity. The ECGF/heparin mediated decrease in HUVEC PAI-l activity and mRNA levels was observed with heparin concentrations as low as 1 ,ug/ml (0.15 U/ml) and was near maximal at concentrations of 5-10 ,g/ml (0.6-1.5 U/ml). These concentrations are within the range of plasma levels obtained in vivo when heparin is used pharmacologically as an antithrombotic agent (36) . In a rabbit model of thrombosis, clot propogation was prevented at heparin concentrations of 0.3-0.5 U/ml (37) .
This observed decrease in PAI-I mRNA appears to be mediated via ECGF and is enhanced in a dose-dependent fashion by the addition of heparin. The mitogenic effect of heparin on HUVEC also appears to be dependent on its interaction with ECGF and is not seen with increased concentrations of heparin alone (up to 900 ,g/ml) (14) . A similar interaction has been observed in fetal rat calvariae where ECGF stimulates DNA synthesis (38) . Heparin has been shown to increase the affinity of ECGF for its receptor, probably through a conformational change in the ECGF peptide (15) . Without supplemental heparin, some decrease in PAI-1 mRNA was still observed in cells grown in the presence of high ECGF concentrations (500 ,ug/ml ECGS). These observations are consistent with heparin's effect on PAI-l mRNA being mediated via its interaction with ECGF. Many other polypeptide growth factors bind heparin; however, physiologic mechanisms resulting from this interaction have not been well characterized (39) . Heparin is an anionic, sulfated, glycosoaminoglycan similar to those found on the endothelial cell surface in vivo and in vitro (40) . A glycosoaminoglycan-growth factor interaction at the endothelial cell surface might play an important role in the regulation of fibrinolysis.
Bovine endothelial PAI-1 mRNA expression is known to vary with different serum preparations used in the culture media (41). In our studies the same lot of bovine serum was used for a given experiment and media were changed in test and control cultures at the same time points. The mechanism(s) responsible for this serum mediated changes in PAI-I mRNA levels is unknown, but could include variations in the concentration of endothelial cell growth factor and/or heparin or related compounds.
We have shown the ECGF/heparin mediated decrease in PAI-1 using both a crude preparation of ECGF from bovine hypothalamus (ECGS) and the purified ECGF (Fig. 6) . Although the data in Fig. 6 were not precisely quantitated, the decrease in PAI-1 mRNA level is less marked when the media were supplemented with the more purified factor. Of note, heparin is used in the purification of this factor and a small amount of heparin (-2 gg/,gg ECGF) is present in the final preparation (Collaborative Research). Although we cannot say whether the heparin used in processing this preparation affected our results, its presence should be considered in the evaluation of experimental data obtained using this product.
The observed decrease in PAI-I mRNA levels in the presence of ECGF/heparin could result from a change in either the rate of PAI-I mRNA synthesis or degradation, that is, either via a transcriptional or posttranscriptional mechanism. A number of other growth factor mediated events have been shown to be regulated, at least in part, at the level oftranscription (39) . PAI-l mRNA contains an unusual 75-bp "AU"-rich sequence in its 3' untranslated region (23) . Similar sequences have been noted in the 3'-untranslated regions of the mRNAs for a number of proteins termed "inflammatory mediators" (42). The 3' "AU"-rich sequence from the cDNA for one of these proteins, granulocyte-macrophage colony-stimulating factor, has been shown to markedly decrease mRNA stability in NIH3T3 cells when inserted into the 3'-untranslated region of a recombinant f3-globin expression construct (43) . Unlike many of these "inflammatory mediators," PAI-1 mRNA is very stable (ti > 8 h, Konkle and Ginsburg, unpublished data) and changes in tj which could result in major differences in steady state mRNA levels may be more difficult to detect.
In summary, we have demonstrated a 3-10-fold decrease in PAI-l activity and mRNA levels in HUVEC with the addition of heparin and ECGF to the culture media. This effect appears to be mediated via ECGF and is enhanced by the addition of heparin. No significant change is seen in tPA mRNA or protein levels under the same conditions. Heparin's primary mode of action as a clinical anticoagulant is thought to occur via activation of antithrombin III with subsequent inhibition of thrombin and factor Xa. An additional profibrinolytic action of heparin resulting in more rapid clot dissolution has long been suspected on clinical grounds, and is supported by in vitro studies (44-46), though the mechanism for this effect has been unknown. If the ECGF/heparin-mediated decrease in PAI-l mRNA also occurs in vivo, this could add significantly to heparin's clinical effect by increasing tPA activity with a subsequent increase in fibrinolysis.
